155 General discussion and future perspectives 32 Studenic P, Hensvold A, Kleyer A, van der Helm-van Mil A, Pratt AG, Sieghart D, Krönke G, Williams R, de Souza S, Karlfeldt S, Johannesson M, Krogh NS, Klareskog L, Catrina AI. 2022; Prospective Studies on the Risk of Rheumatoid Arthritis: The European Risk RA Registry. Front Med. 9. 33 van der Helm-van Mil AHM, Landewé R. 2020; The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA. Ann Rheum Dis. 79:312–5. 34 Mankia K, Siddle H, Di Matteo A, Alpízar-Rodríguez D, Kerry J, Kerschbaumer A, Aletaha D, Emery P. 2021; A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. RMD Open. 7(3):e001768. 35 Siddle HJ, Chapman LS, Mankia K, Zăbălan C, Kouloumas M, Raza K, Falahee M, Kerry J, Kerschbaumer A, Aletaha D, Emery P, Richards SH. 2022; Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. Ann Rheum Dis. 81(2):159–68. 36 Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT. 2009; Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 11(4):R131. 37 Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, et al. 2022; Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 28(6):1256–68. 38 Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, et al. 2021; Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 397(10271):305–17. 39 Akkaya M, Kwak K, Pierce SK. 2020; B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. 20(4):229–38. 40 Anang DC, Ramwadhdoebe TH, Hahnlein JS, van Kuijk B, Smits N, van Lienden KP, Maas M, Gerlag DM, Tak PP, de Vries N, van Baarsen LGM. 2022; Increased Frequency of CD4(+) Follicular Helper T and CD8(+) Follicular T Cells in Human Lymph Node Biopsies during the Earliest Stages of Rheumatoid Arthritis. Cells. 11(7). 41 Isaacs J, Iqbal K. 2019; Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis. Clin Ther. 42 Dirikgil E, Jonker JT, Tas SW, Verburgh CA, Soonawala D, Hak AE, Remmelts HHF, IJpelaar D, Laverman GD, Rutgers A, van Laar JM, Moen HJB, Verhoeven PMJ, Rabelink TJ, Bos WJW, Teng YKO. 2021; Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the Netherlands. Kidney Int Reports. 6(10):2671–8. 43 Musters A, Baeten DLP, Tas SW. 2013; Off-label voorschrijven van biologicals voor zeldzame immunologische aandoeningen: noodzaak voor goede monitoring via het RUBRIC-register. Ned Tijdschr voor Reumatol. 4:37–43. 7
RkJQdWJsaXNoZXIy MTk4NDMw